Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...

Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...

AbstractActivating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, ...

There is a continuing need for improved preclinical mouse models of cancer that more accurately predict therapy outcomes for future clinical translation. Luciferase and bioluminescence have long been ...

NCT03642067 was a phase II study evaluating the combination of relatlimab (LAG-3 inhibitor) and nivolumab (PD-1 inhibitor) in patients with previously treated metastatic pMMR colorectal cancer.

Abstract. Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of ∼15 months. Given the poor survival with the currently approved treatments, ...

The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

We have identified an unmet need for a dedicated home for high-quality computational science papers in the field of cancer research. By 'computational,' I am referring to any paper with a major ...

Individual cohorts with prediagnosis blood samples have insufficient sample size for such studies. Thus, we established “Prospective Early Detection Consortium for Ovarian Cancer” (“PREDICT”)—a ...

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...